Dossier assessment
Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents 2 years of age and older with active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis)
- Patients who have responded inadequately to previous therapy with a conventional synthetic disease-modifying antirheumatic drug: added benefit not proven
- Patients who have responded inadequately to previous therapy with a biological disease-modifying antirheumatic drug: added benefit not proven
Project details
- Project no.
- A25-19
- Commission
- Commission awarded on 04.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-19_en
Connected Projects
-
Dossier assessment
Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed